U.S. Markets closed

FDA places a hold on Ocugen's plan for U.S. trials of the Covid-19 vaccine Covaxin

·3 min read
FDA places a hold on Ocugen's plan for U.S. trials of the Covid-19 vaccine Covaxin
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • OCGN

The Malvern firm has a deal that will get it 45% of sales of the Covid-19 vaccine in the United States, if the product gets FDA approval.